At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Market Closed 04-17 16:08:12
1.500
+0.090
+6.38%
High1.530
Low1.310
Vol7.37M
Open1.370
D1 Closing1.410
Amplitude15.60%
Mkt Cap1.08B
Tradable Cap1.08B
Total Shares722.00M
T/O10.31M
T/O Rate1.02%
Tradable Shares722.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRII-B Files Arbitration Claim Against Vir Biotechnology with US Mediation Service
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.